

## AMENDMENTS

### In the Claims:

~~Please cancel claims 6 and 7.~~

Please amend claim 1 as follows:

1. [AMENDED] A method of treating adverse physiological effects associated with intestinal ischemia/reperfusion wherein the adverse physiological effect is cardiac arrhythmia comprising administering to a subject suffering from the effects of intestinal ischemia/reperfusion an amount of a bactericidal/permeability-increasing (BPI) protein product effective to reduce the duration of cardiac arrhythmia resulting from intestinal ischemia/reperfusion.

## REMARKS

### I. Preliminary Comments

Claim 1 has been amended to recite the full name of "BPI" and has also been amended to recite that the adverse physiological effect is cardiac arrhythmia. This limitation was disclosed in the specification as originally filed and particularly in Example 1 and thus does not constitute new matter. In addition, claim 1 has been amended to recite the result of reducing the duration of cardiac arrhythmia as disclosed in the specification at page 9, lines 20-25 and in Figure 6.

### II. The Outstanding Rejections

Claims 1-10 stand rejected under 35 U.S.C. §112 (first paragraph) on the grounds that the specification fails to provide an enabling disclosure.